Prior authorization request form Form
Dermabrasion Proprietary information of EmblemHealth. © 2025 EmblemHealth & Affiliates POLICY NUMBER LAST REVIEW MG.MM.ME.55a October 10, 2025
Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved.
The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the member meets the criteria for the treatment
or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request preauthorization or
post-payment review. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are
medically necessary. This clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how
to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Health care providers are
expected to exercise their medical judgment in rendering appropriate care.
EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in
the peer reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research
agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical
areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes and welcomes
further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically
necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs
exclude coverage for services or supplies that EmblemHealth considers medically necessary.
If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. Identification of selected brand names
of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test or procedure over
another. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare &
Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication.
EmblemHealth may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The MCG™
Care Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not
constitute the practice of medicine or medical advice. EmblemHealth Services Company, LLC, has adopted this policy in providing management,
administrative and other services to EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC, and Health
Insurance Plan of Greater New York (HIP) related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated
companies under common control of EmblemHealth Inc.
Definitions
Actinic keratosis
(AK)
Actinic keratoses (AKs or solar keratoses) are keratotic macules, papules, or plaques resulting from the intraepidermal proliferation of atypical keratinocytes in response to prolonged exposure to ultraviolet radiation. Although most AKs do not progress to squamous cell carcinoma (SCC), AKs are a concern because the majority of cutaneous SCCs arise from pre-existing AKs, and AKs that will progress to SCC cannot be distinguished from AKs that will spontaneously resolve or persist. Accepted primary treatment modalities include cryotherapy, topical 5-fluorouracil, topical imiquimod, photodynamic therapy (eg, amino levulinic acid [ALA], porfimer sodium), and curettage and electrodesiccation. Dermabrasion Ablative procedure, which removes the epidermis and superficial dermis of the skin. Resurfacing is achieved by planing or sanding; usually by means of a rapidly rotating abrasive tool (wire brush, diamond fraise, or serrated wheel). Laser dermabrasion involves use of an argon laser, ultrapulse carbon dioxide (CO2) laser or flashlamp-pumped pulsed dye laser to resurface the entire face and has been used as an alternative to standard dermabrasion in treating patients with inactive acne with disfiguring scarring. (See Limitations/Exclusions)
Proprietary information of EmblemHealth. © 2025 EmblemHealth & Affiliates
Page 2 of 6 Related Guidelines Cosmetic and Reconstructive Surgery Procedures Phototherapy, Photochemotherapy and Photodynamic Therapy for Dermatologic Conditions Guideline Dermabrasion using controlled surgical scraping (dermaplaning) or carbon dioxide (CO2) laser is considered medically necessary for the removal of squamous cell carcinoma in situ, superficial basal cell carcinomas and pre- cancerous AK lesions; both:
- Conventional methods of removal (e.g., cryotherapy, curettage and excision) are impractical due to the number and distribution of the lesions
- Failed trial of 5-fluorouracil (5-FU) (Efudex) or imiquimod (Aldara); unless contraindicated Limitations/Exclusions
- Dermabrasion is not considered medically necessary for the treatment of active acne vulgaris due to insufficient evidence of therapeutic value.
- Dermabrasion is not considered medically necessary when for the following cosmetic purposes (list not all-
inclusive):
a. Acne scarring (case-by-case review when documentation substantiating medical necessity is
submitted to the plan)
b. Contouring/discoloration/hyperpigmentation (e.g., dermatosis papulosa nigra, rosacea)
c. Dull complexity
d. Ephelides (freckles)
e. Fine/fewer lines and wrinkles
f.
Lentigines (liver spots; aka age spots)
g. Melasma
h. Photoaged skin
i.
Sebaceous hyperplasia (aka senile hyperplasia)
j.
Seborrheic keratoses
k. Skin roughness
l. Tattoo removal Procedure Codes
15780 Dermabrasion; total face (eg, for acne scarring, fine wrinkling, rhytids, general keratosis) 15781 Dermabrasion; segmental, face 15782 Dermabrasion; regional, other than face 15783 Dermabrasion; superficial, any site (eg, tattoo removal)
Proprietary information of EmblemHealth. © 2025 EmblemHealth & Affiliates
Page 3 of 6
ICD-10 Diagnoses
C44.01
Basal cell carcinoma of skin of lip
C44.02
Squamous cell carcinoma of skin of lip
C44.111
Basal cell carcinoma of skin of unspecified eyelid, including canthus
C44.112
Basal cell carcinoma of skin of right eyelid, including canthus
C44.1121
Basal cell carcinoma of skin of right upper eyelid, including canthus
C44.1122
Basal cell carcinoma of skin of right lower eyelid, including canthus
C44.119
Basal cell carcinoma of skin of left eyelid, including canthus
C44.1191
Basal cell carcinoma of skin of left upper eyelid, including canthus
C44.1192
Basal cell carcinoma of skin of left lower eyelid, including canthus
C44.121
Squamous cell carcinoma of skin of eyelid, including canthus, UNSPECIFIED
C44.1221
Squamous cell carcinoma of skin of right upper eyelid, including canthus
C44.1222
Squamous cell carcinoma of skin of right lower eyelid, including canthus
C44.1291
Squamous cell carcinoma of skin of left upper eyelid, including canthus
C44.1292
Squamous cell carcinoma of skin of left lower eyelid, including canthus
C44.211
Basal cell carcinoma of skin of unspecified ear and external auricular canal
C44.212
Basal cell carcinoma of skin of right ear and external auricular canal
C44.219
Basal cell carcinoma of skin of left ear and external auricular canal
C44.221
Squamous cell carcinoma of skin of unspecified ear and external auricular canal
C44.222
Squamous cell carcinoma of skin of right ear and external auricular canal
C44.229
Squamous cell carcinoma of skin of left ear and external auricular canal
C44.310
Basal cell carcinoma of skin of unspecified parts of face
C44.311
Basal cell carcinoma of skin of nose
C44.319
Basal cell carcinoma of skin of other parts of face
C44.320
Squamous cell carcinoma of skin of other an unspecified parts of face
C44.321
Squamous cell carcinoma of skin of nose
C44.329
Squamous cell carcinoma of skin of other parts of face
C44.41
Basal cell carcinoma of skin of scalp and neck
C44.42
Squamous cell carcinoma of skin of scalp and neck
C44.510
Basal cell carcinoma of anal skin
C44.511
Basal cell carcinoma of skin of breast
C44.519
Basal cell carcinoma of skin of other part of trunk
C44.520
Squamous cell carcinoma of anal skin
C44.521
Squamous cell carcinoma of skin of breast
C44.529
Squamous cell carcinoma of skin of other part of trunk
Proprietary information of EmblemHealth. © 2025 EmblemHealth & Affiliates
Page 4 of 6
C44.611
Basal cell carcinoma of skin of unspecified upper limb, including shoulder
C44.612
Basal cell carcinoma of skin of right upper limb, including shoulder
C44.619
Basal cell carcinoma of skin of left upper limb, including shoulder
C44.621
Squamous cell carcinoma of skin of unspecified upper limb, including shoulder
C44.622
Squamous cell carcinoma of skin of right upper limb, including shoulder
C44.629
Squamous cell carcinoma of skin of left upper limb, including shoulder
C44.711
Basal cell carcinoma of skin of unspecified lower limb, including hip
C44.712
Basal cell carcinoma of skin of right lower limb, including hip
C44.719
Basal cell carcinoma of skin of left lower limb, including hip
C44.721
Squamous cell carcinoma of skin of unspecified lower limb, including hip
C44.722
Squamous cell carcinoma of skin of right lower limb, including hip
C44.729
Squamous cell carcinoma of skin of left lower limb, including hip
C44.81
Basal cell carcinoma of overlapping sites of skin
C44.82
Squamous cell carcinoma of overlapping sites of skin
C44.91
Basal cell carcinoma of skin, unspecified
C44.92
Squamous cell carcinoma of skin, unspecified
D48.5
Neoplasm of uncertain behavior of skin
L57.0
Actinic keratosis
References
Achauer BM. Lasers in plastic surgery: Current practice. Plast Reconstr Surg. 1997;99(5):1442-1450.
Ayhan S, Baran CN, Yavuzer R, et al. Combined chemical peeling and dermabrasion for deep acne and posttraumatic scars as well as
aging face. Plast Reconstr Surg. 1998;102(4):1238-1246.
Baker TM. Dermabrasion. As a complement to aesthetic surgery. Clin Plast Surg. 1998;25(1):81-88.
Barnaby JW, Styles AR, Cockerell CJ. Actinic keratoses. Differential diagnosis and treatment. Drugs Aging. 1997;11(3):186-205.
Bhalla M, Thami GP. Microdermabrasion: Reappraisal and brief review of literature. Dermatol Surg. 2006;32(6):809-814.
Bhate K, Williams HC. What's new in acne? An analysis of systematic reviews published in 2011-2012. Clin Exp Dermatol.
2014;39(3):273-277; quiz 277-278.
Blome-Eberwein SA, Roarabaugh C, Gogal C, Eid S. Exploration of nonsurgical scar modification options: Can the irregular surface of
matured mesh graft scars be smoothed with microdermabrasion? J Burn Care Res. 2012;33(3):e133-e140.
Chiarello SE. CO2 laser for actinically damaged skin. Dermatol Surg. 1998;24(8):933-934.
Coleman WP 3rd, Yarborough JM, Mandy SH. Dermabrasion for prophylaxis and treatment of actinic keratoses. Dermatol Surg.
1996;22(1):17-21.
CMS. National Coverage Determination. Treatment of Actinic Keratosis. https://www.cms.gov/medicare-coverage-
database/view/ncd.aspx?NCDId=129&ncdver=1&DocID=250.4&bc=gAAAAAgAAAAAAA%3d%3d&. Accessed October 10, 2025.
Garg T, Chander R, Jain A. Combination of microdermabrasion and 5-fluorouracil to induce repigmentation in vitiligo: An
observational study. Dermatol Surg. 2011;37(12):1763-766.
Grevelink JM, White VR. Concurrent use of laser skin resurfacing and punch excision in the treatment of facial acne scarring.
Dermatol Surg. 1998;24(5):527-530.
Grimes PE. Microdermabrasion. Dermatol Surg. 2005;31(9 Pt 2):1160-1165; discussion 1165.
Proprietary information of EmblemHealth. © 2025 EmblemHealth & Affiliates
Page 5 of 6
Gupta AK, Inniss K, Wainwright R, et al. Interventions for actinic keratoses (Protocol for Cochrane Review). Cochrane Database Syst
Rev. 2003;(4):CD004415.
Helfand M, Gorman AK, Mahon S, et al. Actinic keratosis. Final Report. Evidence-Based Practice Centers. Submitted to the Agency
for Healthcare Research and Quality under contract 290-97-0018, task order no. 6. Portland, OR: Oregon Health & Science
University Evidence-Based Practice Center; May 19, 2001.
Hopkins JD, Smith AW, Jackson IT. Adjunctive treatment of congenital pigmented nevi with phenol chemical peel. Plast Reconstr
Surg. 2000;105(1):1-11.
Hruza GJ. Dermabrasion. Facial Plast Surg Clin North Am. 2001;9(2):267-281, ix.
Jordan R, Cummins C, Burls A. Laser resurfacing of the skin for the improvement of facial acne scarring. DPHE Report No. 11.
Birmingham:, UK: West Midlands Health Technology Assessment Collaboration, Department of Public Health and Epidemiology,
University of Birmingham (WMHTAC); 1998.
Jordan R, Cummins C, Burls A. Laser resurfacing of the skin for the improvement of facial acne scarring: A systematic review of the
evidence. Br J Dermatol. 2000;142(3):413-423.
Jordan RE, Cummins CL, Burls AJE, Seukeran DC. Laser resurfacing for facial acne scars. Cochrane Database Syst Rev.
2000;(3):CD001866.
Karimipour DJ, Karimipour G, Orringer JS. Microdermabrasion: An evidence-based review. Plast Reconstr Surg. 2010;125(1):372-377
Le Pillouer PA, Casanova D. Scarring process after induced dermabrasion. Wound Repair Regen. 2002;10(2):113-115.
Mandy SH. Dermabrasion. Semin Cutan Med Surg. 1996;15(3):162-169.
Matarasso SL, Hanke CW, Alster TS. Cutaneous resurfacing. Dermatol Clin. 1997;15(4):569-582.
National Comprehensive Cancer Network. NCCN Guidelines Squamous Cell Skin Cancer. Version 1.2024.
http://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf. Accessed October 10, 2025.
Nguyen T. Dermatology procedures: Microdermabrasion and chemical peels. FP Essent. 2014;426:16-23.
Orentreich N, Orentreich DS. Dermabrasion. As a complement to dermatology. Clin Plast Surg. 1998;25(1):63-80.
Patel L, McGrouther D, Chakrabarty K. Evaluating evidence for atrophic scarring treatment modalities. JRSM Open.
2014;5(9):2054270414540139.
Rice P, Brown RF, Lam DG, et al. Dermabrasion -- a novel concept in the surgical management of sulphur mustard injuries. Burns.
2000;26(1):34-40.
Samuel M, Brooke RCC, Hollis S, Griffiths CEM. Interventions for photodamaged skin. Cochrane Database Syst Rev.
2005;(1):CD001782.
Solish N, Raman M, Pollack SV. Approaches to acne scarring: A review. J Cutan Med Surg. 1998;2 Suppl 3:24-32.
Specialty matched clinical peer review.
Victor FC, Gelber J, Rao B. Melasma: A review. J Cutan Med Surg. 2004;8(2):97-102.
Weinstein C. Carbon dioxide laser resurfacing. Long-term follow-up in 2123 patients. Clin Plast Surg. 1998;25(1):109-130.
West TB. Laser resurfacing of atrophic scars. Dermatol Clin. 1997;15(3):449-457.
Revision History
Company(ies)
DATEREVISION EmblemHealth Oct. 10, 2025 Added squamous cell carcinoma in situ as a covered indication ConnectiCare Aug. 5, 2019 ConnectiCare adopts the clinical criteria of its parent corporation Emblem Health
Proprietary information of EmblemHealth. © 2025 EmblemHealth & Affiliates
Page 6 of 6
Walk through this policy with us
Review how this policy can be converted into cited criteria, prior authorization checks, and operational automation.